Ono Pharmaceutical

{{Short description|Japanese pharmaceutical company}}

{{Use mdy dates|date=January 2019}}

{{Infobox company

|name = Ono Pharmaceutical Co., Ltd.

|native_name = 小野薬品工業

|native_name_lang = ja

|logo = Ono Pharmaceutical company logo.svg

|logo_size = 150px

|type = Public (K.K)

|traded_as = {{TYO|4528}}

|ISIN = {{ISIN|sl=n|pl=y|JP3197600004}}

|foundation = {{Start date and age|1717}} as Fushimiya Ichibei apothecary

|founder = Ichibei Ono I

|hq_location_city = Chuo-ku, Osaka, 541-8564

|hq_location_country = Japan

|key_people = Gyo Sagara
(President and CEO)

|industry = Pharmaceuticals

|products = {{unbulleted list |Pharmaceuticals|Diagnostic reagents}}

|revenue = {{increase}} USD 6.3 billion (FY 2023)

|net_income = USD 848.1 million (FY 2023)

|num_employees = 3,687 (2023)

|area_served = Worldwide

|homepage = {{Official website|https://www.ono.co.jp/eng/index.html}}

|footnotes = {{cite web |url=https://www.ono.co.jp/eng/about/company_profile.html |title=Company Profile |publisher=Ono Pharmaceutical |access-date=January 30, 2019}}{{cite web |url=https://asia.nikkei.com/Companies/Ono-Pharmaceutical-Co.-Ltd |title=Company Profile |work=Nikkei Asian Review |publisher=Nikkei Inc. |access-date=January 30, 2019}}{{cite web |url=https://markets.ft.com/data/equities/tearsheet/profile?s=4528:TYO |title=About the company |publisher=Financial Times |access-date=January 30, 2019}}}}

File:Headquarters of Ono Pharmaceutical Co.,Ltd..JPG, Japan]]

{{nihongo|Ono Pharmaceutical Co., Ltd.|小野薬品工業株式会社|Ono Yakuhin Kōgyō Kabushiki-gaisha}} is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka.,[https://www.ono.co.jp/eng/about/manufacturing.html Ono Pharmaceutical - Manufacturing] and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.[https://www.ono.co.jp/eng/rd/research_organization.html Ono Pharmaceutical - Research & Development]

Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono ({{Langx|ja|小野市兵衛}}) started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. ({{Langx|ja|小野薬品工業株式会社}}) in 1948.{{cite book|author=P. Reed Maurer |title=They Do Well Who Do Good: Insights into Japan's Pharmaceutical Industry |date=January 25, 2013 |isbn=978-1-4669-5347-5 |page=132|publisher=Trafford }}

Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.{{cite web|url=https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=876950|title=Company Overview of Ono Pharmaceutical Co., Ltd.|website=bloomberg.com|access-date=2018-10-04}}

Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.{{cite web|url=https://www.nippon.com/en/column/g00268/|title=Spotlight on New Cancer Immunotherapy: Ono Pharmaceutical's Opdivo|website=Nippon.com|date=February 9, 2016 |access-date=2018-10-04}}

In 2024, Harvard University and Ono Pharmaceutical (ONO) entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work.{{cite web |website=TechTransferCentral. |title= Harvard partners with Ono Pharma to accelerate development of novel therapeutics

|url=https://techtransfercentral.com/2024/03/18/harvard-partners-with-ono-pharma-to-accelerate-development-of-novel-therapeutics/|date=March 18, 2024 }}